Aurinia Pharma U.S., INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$6.7Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
11,989clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2021 $1.5M
2022 $2.3M
2023 $1.6M
2024 $929K
2025 $438K

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Nephrology (Internal Medicine) $3.4M
Rheumatology $2.5M
Internal Medicine $132K
Family $117K
Physician Assistant $75K
Nurse Practitioner $70K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
German Hernandez El Paso, TX Nephrology (Internal Medicine) $303,215.14
Tina Kochar Galveston, TX Nephrology (Internal Medicine) $239,181.70
Jorge Larranaga Kissimmee, FL Nephrology (Internal Medicine) $230,594.97
Abdul Abdellatif Webster, TX Nephrology (Internal Medicine) $182,921.29
Sreedhara Alla Shreveport, LA Nephrology (Internal Medicine) $155,569.80
Laura Geraldino Pardilla New York, NY Rheumatology $143,403.85
Gerald Appel New York, NY Nephrology (Internal Medicine) $142,337.45
Sanjay Chabra El Paso, TX Rheumatology $138,047.55
Michael Aaronson Lincoln, NE Nephrology (Internal Medicine) $137,580.72
Joshua Kaplan Newark, NJ Nephrology (Internal Medicine) $131,972.64

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.